最新消息
News
漢康生技三靶點融合蛋白HCB301完成兩個劑量組安全性評估 全球臨床推進再跨一步
漢康生技（HanchorBio, KY-7827）宣布，其以自主 FBDB™ 多功能融合蛋白平台 開發的 三靶點創新藥 HCB301，已完成臨床一期前兩個劑量組安全性觀察，結果顯示耐受性良好，具臨床開發潛力。HCB301 兼具阻斷 SIRPα-CD47、PD-1/PD-L1 及 TGFβ 三大機制，能同時啟動先天與適應性免疫、克服腫瘤免疫抑制，為難治型癌症帶來新療法。該試驗（NCT06487624）正於中美兩地進行，台灣審查中，顯示漢康在免疫融合蛋白領域的全球開發邁出重要一步。
11 月 11, 2025
Read more
HanchorBio Presents Preclinical Data at the SITC 2025 on HCB301, a First-in-Class Tri-Specific Immunotherapy Targeting SIRPα-CD47, PD-1/PDL1, and TGFβ 漢康生技在SITC 2025公佈HCB301臨床前資料首創三特異性免疫療法靶向SIRPα-CD47、PD-1/PD-L1和TGFβ
Novel fusion protein shows potent macrophage activation […]
11 月 06, 2025
Read more
漢康HCB101再現臨床突破 頭頸癌試驗起始低劑量組患者2/2出現腫瘤大幅縮小
全球臨床階段生技公司漢康生技（7827）宣布，旗下免疫治療新藥HCB101在臨床試驗中再度傳來捷報。繼二線胃癌 […]
10 月 30, 2025
Read more
漢康HCB101二線胃癌最新數據亮眼 近九成患者腫瘤顯著縮小
全球臨床階段生技公司漢康生技（7827）公布旗下免疫治療新藥 HCB101 的最新臨床試驗數據，顯示該藥在晚期 […]
10 月 29, 2025
Read more
HanchorBio Strengthens R&D Strategy with Productive SAB Meeting Focusing on Promising HCB101 Data and Pipeline Innovation
HanchorBio announced the successful completion of its latest Scientific Advisory Board (SAB) meeting. Chaired by Professor Mingyi Chen (UT Southwestern Medical Center), the SAB brings together global leaders from institutions such as The Ohio State University, University of Michigan, Tsinghua University, and National Taiwan University to review HanchorBio’s clinical progress, translational insights, and pipeline strategy across oncology and autoimmune diseases.
10 月 08, 2025
Read more
HanchorBio Strengthens R&D Strategy with Productive SAB Meeting Focusing on Promising HCB101 Data and Pipeline Innovation 漢康生技強化研發策略 聚焦HCB101臨床亮眼數據與創新管線的專家諮詢委員會（SAB）會議圓滿舉行
HanchorBio announced the successful completion of its latest Scientific Advisory Board (SAB) meeting. Chaired by Professor Mingyi Chen (UT Southwestern Medical Center), the SAB brings together global leaders from institutions such as The Ohio State University, University of Michigan, Tsinghua University, and National Taiwan University to review HanchorBio’s clinical progress, translational insights, and pipeline strategy across oncology and autoimmune diseases.
10 月 08, 2025
Read more
HanchorBio Receives Third Taiwan TFDA Approval for HCB101 Combination Therapy in Advanced Gastric Cancer
HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announced that the Taiwan Food and Drug Administration (TFDA) has approved a third investigator-initiated trial (IIT) evaluating HCB101 in combination with zolbetuximab and chemotherapy for the first-line treatment of patients with HER2-negative, CLDN18.2-positive advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
7 月 17, 2025
Read more